Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

SinoBio Acquires Stake in Belgium Inhaler Company in $200 Million Deal

publication date: Mar 23, 2021

Sino Biopharm announced a deal worth up to $200 million to acquire a 60% stake in Softhale, a Belgium company that has developed a novel Soft Mist Inhaler. Sino Bio will pay $110 million upfront plus a share of profits. The Softhaler® device is a technically flexible delivery technology that increases spray volume, allowing more active ingredients than current SMI devices. It is aimed at asthma or COPD therapies. Sino Bio acquired the 60% stake from New Rhein Healthcare; it also acquired a 25% Softhale share from PM Equity Partner. More details....

Stock Symbol: (HK: 1177)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.